High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare
In this cohort study, high-cost drugs were more commonly prescribed among patients enrolled in TM and diagnosed with CRC. A similar pattern was not observed for patients with NSCLC, perhaps because clinical evidence suggests survival benefits to be associated only with certain drugs, all of which are expensive. Nonetheless, MA was modestly associated with reduced high-cost drug utilization and may reduce overall treatment costs.
Authors
- Marcelo Coca Perraillon (ORCID: https://orcid.org/0000-0003-3355-3720)
- Cathy J. Bradley (ORCID: https://orcid.org/0000-0001-9429-6567)
- Lindsay M. Sabik (ORCID: https://orcid.org/0000-0002-0613-4929)
- Rifei Liang (ORCID: https://orcid.org/0000-0003-3260-7213)
- Richard C. Lindrooth (ORCID: https://orcid.org/0000-0001-9538-9749)
Institutions
- Colorado School of Public Health (US)
- University of Pittsburgh (US)
- University of Colorado Cancer Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1001/jamahealthforum.2024.4868
- Citations
- 6
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 18.79